All News

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it is attending Oxford Global’s Immuno 2024 Event in London on 25th and 26th of April 2024.   Physiomics’ Head of Business Development, Hayley Close will be attending the event which brings together over 400 experts in the field of...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it is attending BioTrinity 2024, OBN’s leading life sciences conference, in London on 23rd and 24th of April 2024.   Physiomics’ Head of Business Development, Hayley Close will be attending the event which aims to catalyse growth in the life...

Read More

Leading mathematical modelling company, supporting oncology drug development.     From us to you - curated cutting-edge research and insights. Welcome to our newsletter, where we share the latest updates from Physiomics and offer insights on the pivotal news shaping the dynamic world of drug development.     Top news   Exciting new project with existing large pharma client   Physiomics are pleased to share that we have been awarded a new PKPD modelling project...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, recently provided a brief update in-line with its interim results via Investor Meet Company and has updated its website with the presentation.   The presentation and Q&A from the meeting are now available at the Company’s website: https://www.physiomics.co.uk/portfolio-item/investor-presentation-interim-results-and-company-update/     Enquiries:   Physiomics plc Dr Jim Millen, Non-Executive Chairman, +44 (0)1235...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has been awarded a substantial new contract by an existing large pharma client.  The project involves Pharmacokinetic-Pharmacodynamic (PKPD) modelling in the field of DNA damage/ repair field and will help inform clinical dose and scheduling decisions. The value...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it is attending the 14th Annual World ADC Event in London on 13th and 14th of March 2024.   Physiomics’ CEO, Dr Pete Sargent and Head of Business Development, Hayley Close will be attending the event which is Europe’s definitive...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it will be posting its interim results on Thursday 7 March 2024.   The Company will provide a live presentation update in-line with these results via Investor Meet Company on 18 March 2024 at 12:00 pm GMT. During this presentation,...

Read More

Leading mathematical modelling company, supporting oncology drug development.     From us to you - curated cutting-edge research and insights. Welcome to our newsletter, where we share the latest updates from Physiomics and offer insights on the pivotal news shaping the dynamic world of drug development.     Top news     Welcoming Peter Sargent as newly appointed CEO   Peter, who joined Physiomics in September 2023 as Chief Operating Officer, has now been appointed to...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has been chosen by The University of Sheffield (the “University”) to support a grant funded project focused on an insect (Fruit fly) model of cancer treatment.  The value of this work to Physiomics will be £45k and...

Read More